

Millennium Surgical Center Converts to Clearant Processed® Tissue as Their Primary Source

Sterilized Tissue to Protect the Safety of Patients

LOS ANGELES, CA—(MARKET WIRE)—February 13, 2008 – Clearant, Inc. (OTC BB: CLRA), owner of the Clearant Process®, designed to substantially reduce all types of pathogens in biological products including HIV, today announced that it has been selected by Millennium Surgical Center of Cherry Hill, New Jersey, as its primary source of allograft tissue. Millennium is the first surgical facility in New Jersey to exclusively use Clearant Processed® allograft tissue for use in reconstructive knee surgery.

“Recent, well-publicized incidents of unsafe, tainted or improperly procured human tissue were our primary reason to seek out and select Clearant as our primary tissue allograft provider. There is no safer graft tissue than that treated with the Clearant Process® today” said Larry Rosenberg, MD., a knee and shoulder reconstructive sports surgeon at Millennium Surgical Center.

“My pre-op patients now often ask me whether the ligament implant they are about to receive has been fully sterilized,” said Dr. Alexander Sapega, a member of the governing board of Millennium Surgical Center who was asked in 2005 to serve on a Board of Neutral Physician Examiners by the NFL Players Association and the NFL Management Council. “I would never want to be put in the position of receiving a recall notice and informing one of my patients that their recently implanted cruciate ligament allograft had safety concerns due to a possible lack of sterility. For this reason, we’ve chosen the Clearant Process®.”

Dr. Sapega, a past Sports Medicine Director and Associate Professor at the University of Pennsylvania, spent several months researching industry practices, the Clearant Process® and meeting with Clearant personnel before recommending Clearant to the center and his fellow surgeons.

“The Millennium surgical team has an impressive commitment to patient safety and a researchers approach to understanding the science behind the Clearant technology,” said Jon Garfield, Clearant Chief Executive Officer. “We are very pleased that they have chosen our Clearant Process® to increase the safety of their patients.”

The Millennium Surgical Center is South Jersey’s newest orthopedic and neurological ambulatory surgery center. Millennium is a Titan Health Corporation managed facility. Millennium Knee and Sports Medicine surgeons Alexander Sapega, MD, Larry Rosenberg, MD, Michael Barrett, DO and spine surgeon Evan O’Brien, MD are all advocates for the Clearant Processed® tissue, which achieves a terminal sterility assurance level of 10⁻⁶ without compromising the structural properties of the tissue implants.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process®, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant

or protein. The Company has distributed implants sterilized by the Clearant Process® directly to surgeons, hospitals and clinics since June 2006. In addition, Clearant licenses the Clearant Process®, and provides its patented sterilization services, to tissue banks and other biological products manufacturers. To date more than 8,000 patients have been successfully implanted with Clearant Process® sterile implants supplied by one of the Company's licensed partners. The Clearant Process®, unlike its various competitors, is applied in the final packaging and reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at <http://www.sec.gov>.

Contact:

Clearant, Inc.

Jon Garfield

Chief Executive Officer

310-479-4570

www.clearant.com